认知障碍高危因素数据集

资源背景与意义​​：本数据集面向认知障碍疾病机制研究、临床诊疗优化及高危人群早期预测需求，基于多中心联合建立的标准化神经科学研究平台产生。数据通过整合临床表型、神经影像、生物样本及神经心理测评等多维度信息，为探索阿尔茨海默病（AD）与卒中后认知障碍（PSCI）的病理关联、病程演变及生物标志物筛选提供高质量队列支持，对推动精准诊疗策略和预防干预具有重要意义。
​​来源与产生方法​​：天坛医院为主要研究单位，以中国北方人群为主的多中心协作建立的认知障碍纵向研究队列，覆盖认知正常对照组、阿尔茨海默病组及卒中后认知障碍高危组3类人群，共纳入799名受试者。数据采集遵循以下标准化流程：
​​临床信息​​：通过统一电子临床报告表（eCRF）记录人口学特征、病史、用药等基本信息，由专职临床研究助理（CRA）进行逻辑核查与质控。主中心统一MRI序列参数的影像采集。覆盖MoCA、MMSE、CDR等多项标准化量表，主中心统一培训，确保跨中心数据一致性。
​​数据内容与体量​​：
​​队列构成​​：
​​认知正常对照组（NC）​​：40-100岁无认知障碍病史人群（排除其他神经系统/全身性疾病干扰）；
​​阿尔茨海默病组（AD）​​：符合临床标准诊断的人群，部分患者满足NINCDS-ADRDA诊断标准的确诊患者；
​​卒中后认知障碍高危组（PSCI-HR）​​：首次卒中发作且基线无认知障碍人群。
​​​​随访计划​​：NC与AD组每年随访至2年；PSCI-HR组于卒中后3个月、6个月、1年及2年进行动态评估。
​​数据体量​​：本次数据上传涉及临床数据，累计20Mb。
​​应用场景​​：本数据集适用于神经退行性疾病跨组学关联分析、认知衰退轨迹建模、影像生物标志物挖掘及多中心研究标准化方法验证，为临床研究者、公共卫生机构及药企研发提供高信效度数据支撑。

Resource Background and Significance
This dataset is developed based on a standardized neuroscience research platform jointly established by multiple centers, targeting the needs of research on cognitive impairment disease mechanisms, optimization of clinical diagnosis and treatment, and early prediction of high-risk populations. It integrates multi-dimensional information including clinical phenotypes, neuroimaging, biological samples, and neuropsychological assessments, providing high-quality cohort support for exploring the pathological associations, disease course progression, and biomarker screening of Alzheimer's Disease (AD) and Post-Stroke Cognitive Impairment (PSCI). This dataset holds significant importance for promoting precision diagnosis and treatment strategies and preventive interventions.

Source and Generation Methods
Tiantan Hospital serves as the lead research institution. A longitudinal cohort study on cognitive impairment was established via multi-center collaboration primarily recruiting northern Chinese populations, covering three groups of subjects: cognitively normal control group, Alzheimer's disease group, and high-risk post-stroke cognitive impairment group, with a total of 799 participants enrolled. The data collection follows the standardized workflow as follows:

Clinical Information
Basic information such as demographic characteristics, medical history, and medications are recorded via unified electronic Case Report Forms (eCRF), with logical verification and quality control conducted by full-time Clinical Research Associates (CRAs). Imaging data are acquired with unified MRI sequence parameters coordinated by the central coordinating site. Multiple standardized neuropsychological scales including the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and Clinical Dementia Rating (CDR) are administered, and all participating centers receive unified training from the lead center to ensure cross-site data consistency.

Data Content and Scale

Cohort Composition

Cognitively Normal Control Group (NC): Individuals aged 40–100 years with no history of cognitive impairment, excluding those with confounding neurological or systemic diseases;

Alzheimer's Disease Group (AD): Individuals diagnosed per clinical standards, with a subset meeting the definitive diagnostic criteria of NINCDS-ADRDA;

High-Risk Post-Stroke Cognitive Impairment Group (PSCI-HR): Individuals who experienced their first stroke and had no cognitive impairment at baseline.

Follow-up Schedule
The NC and AD groups will undergo annual follow-up for up to 2 years; the PSCI-HR group will receive dynamic assessments at 3 months, 6 months, 1 year, and 2 years post-stroke.

Data Volume
The currently uploaded clinical data totals 20 Mb.

Application Scenarios
This dataset is applicable for cross-omic association analyses of neurodegenerative diseases, cognitive decline trajectory modeling, imaging biomarker discovery, and validation of standardized multi-center research methodologies, providing high-reliability and valid data support for clinical researchers, public health agencies, and pharmaceutical research and development teams.